经导管瓣膜修复系统治疗重度三尖瓣反流的可行性研究
CLASP TR早期可行性研究是一项美国单臂、多中心、前瞻性研究,评估PASCAL经导管瓣膜修复系统治疗三尖瓣反流的安全性与可行性。34例有症状的重度三尖瓣反流患者中,85%成功植入,30天时85%的患者三尖瓣反流严重程度至少降低1级,主要不良事件率为5.9%,无心血管死亡、卒中、心肌梗死、肾脏并发症或再次干预,患者功能状态、运动能力和生活质量显著改善。
要点
- PASCAL系统治疗重度三尖瓣反流30天主要不良事件率5.9%,无死亡或再次干预。
- 85%植入患者三尖瓣反流严重程度至少降低1级,52%达到中度或以下。
核心结论
- 在该早期经验中,PASCAL经导管瓣膜修复系统按预期发挥作用,显著降低三尖瓣反流,安全性良好,主要不良事件率低,无死亡或再次干预,并显著改善功能状态、运动能力和生活质量。
研究设计与样本
- 美国单臂、多中心、前瞻性CLASP TR早期可行性研究,纳入34例经优化药物治疗仍有症状的三尖瓣反流患者,由当地心脏团队和中心筛查委员会审核。
- 数据在基线、出院和30天随访时收集,由独立临床事件委员会和超声核心实验室审核。
主要发现
- 34例患者平均年龄76岁,53%为女性,平均STS评分7.3%,88%有心房颤动/扑动,97%为重度或以上三尖瓣反流,79%为NYHA III/IV级。
- 主要不良事件率为5.9%,无心血管死亡、卒中、心肌梗死、肾脏并发症或再次干预发生。
临床怎么用
- 对于有症状的重度三尖瓣反流患者,在优化药物治疗基础上,PASCAL经导管瓣膜修复系统可作为可行的治疗选择,但需由心脏团队评估。
- 术后30天随访显示三尖瓣反流显著降低且安全性良好,支持进一步开展更大规模研究验证长期效果。
局限性
- 本研究为单臂、早期可行性研究,样本量小(34例),缺乏对照组,结论需在更大规模随机试验中验证。
- 随访时间仅30天,长期疗效和安全性尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tricuspid regurgitation (TR) is a prevalent disease with limited treatment options. OBJECTIVES: This is the first 30-day report of the U.S. single-arm, multicenter, prospective CLASP TR early feasibility study of the PASCAL transcatheter valve repair system in the treatment of TR. METHODS: Patients with symptomatic TR despite optimal medical therapy, reviewed by the local heart team and central screening committee, were eligible for the study. Data were collected at baseline, discharge, and the 30-day follow-up and were reviewed by an independent clinical events committee and echocardiographic core laboratory. Feasibility endpoints included safety (composite major adverse event [MAE] rate), echocardiographic, clinical, and functional endpoints. RESULTS: Of the 34 patients enrolled in the study, the mean age was 76 years, 53% were women, the mean Society of Thoracic Surgeons score was 7.3%, 88% had atrial fibrillation/flutter, 97% had severe or greater TR, and 79% had New York Heart Association (NYHA) functional class III/IV symptoms. Twenty-nine patients (85%) received implants; at 30 days, 85% of them achieved a TR severity reduction of at least 1 grade, with 52% with moderate or less TR (p < 0.001). The MAE rate was 5.9%, and none of the patients experienced cardiovascular mortality, stroke, myocardial infarction, renal complication, or reintervention. Eighty-nine percent of the patients improved to NYHA functional class I/II (p < 0.001), the mean 6-min walk distance improved by 71 m (p < 0.001), and the mean Kansas City Cardiomyopathy Questionnaire score improved by 15 points (p < 0.001). CONCLUSIONS: In this early experience, the repair system performed as intended, with substantial TR reduction, favorable safety results with a low MAE rate, no mortality or reintervention, and significant improvements in functional status, exercise capacity, and quality of life. (Edwards CLASP TR EFS [CLASP TR EFS]; NCT03745313).
引用
- Kodali S, Hahn RT, Eleid MF, et al. Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2021. PMID: 33509390. doi:10.1016/j.jacc.2020.11.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。